Drugs /

clr 131

Back to Drugs List

Overview

NCI Definition [1]:
A radiopharmaceutical composed of a mixture of proprietary phospholipid ethers (CLR 1404) that are covalently linked to the cytotoxic radioisotope iodine I 131 (iodine-131), with potential antineoplastic activity. Upon administration of CLR 131, the phospholipid ether (PLE) moiety is selectively taken up by lipid raft microdomains expressed on tumor cells and accumulates in the cytoplasm of tumor cells;. CLR 131 is not taken up by normal, healthy cells. This delivers cytotoxic iodine I 131 directly to and induces cell death in tumor cells. PLEs allows for targeted delivery of the radioisotope.

Clinical Trials

View Clinical Trials for clr 131

Clr 131 has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating clr 131, 2 are phase 1 (2 open).

Lymphoma, malignant central nervous system neoplasm, and malignant head and neck neoplasm are the most common diseases being investigated in clr 131 clinical trials [2].

Drug Details

Synonyms [2]:
i-131 ple analogue clr1404, 131i-clr1404, clr 1404 i-131, i-131 ple analogue clr1404, iodine i 131 phospholipid ether analogue clr1404, pdc clr 131, [131i]-clr1404, i-131-clr1404, phospholipid ether-drug conjugate clr 131
NCIT ID [1]:
C84879

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.